Merck Pre-Tax Profit Margin 2006-2018 | MRK

Current and historical pre-tax profit margin for Merck (MRK) from 2006 to 2018. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Merck pre-tax profit margin for the twelve months ending June 30, 2018 was $0.053B. Merck pre-tax profit margin for the three months ending June 30, 2018 was $0.020B, representing a 18.85% decline from the same quarter last year.
Merck Annual Pre-Tax Profit Margin
2017 16.25
2016 11.70
2015 13.67
2014 40.92
2013 12.59
2012 18.49
2011 15.26
2010 3.60
2009 55.75
2008 41.64
2007 14.43
2006 27.49
2005 33.45
Merck Quarterly Pre-Tax Profit Margin
Q2 2018 19.93
Q1 2018 13.40
Q4 2017 18.01
Q3 2017 1.94
Q2 2017 24.56
Q1 2017 21.23
Q4 2016 -13.41
Q3 2016 27.40
Q2 2016 15.28
Q1 2016 17.44
Q4 2015 7.99
Q3 2015 23.80
Q2 2015 8.25
Q1 2015 14.65
Q4 2014 112.68
Q3 2014 14.11
Q2 2014 17.30
Q1 2014 20.37
Q4 2013 10.82
Q3 2013 13.82
Q2 2013 11.31
Q1 2013 14.53
Q4 2012 11.37
Q3 2012 19.31
Q2 2012 21.77
Q1 2012 21.37
Q4 2011 12.86
Q3 2011 19.56
Q2 2011 13.76
Q1 2011 14.93
Q4 2010 -5.81
Q3 2010 4.48
Q2 2010 10.94
Q1 2010 5.39
Q4 2009 64.03
Q3 2009 83.92
Q2 2009 33.35
Q1 2009 33.11
Q4 2008 32.44
Q3 2008 24.26
Q2 2008 34.53
Q1 2008 76.31
Q4 2007 -49.00
Q3 2007 33.99
Q2 2007 36.53
Q1 2007 39.08
Q4 2006 15.09
Q3 2006 22.75
Q2 2006 36.53
Q1 2006 36.42
Q4 2005 26.36
Q3 2005 36.90
Q2 2005 35.21
Q1 2005 35.82
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $186.199B $40.122B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $360.770B 17.24
Pfizer (PFE) United States $250.556B 14.67
Novartis AG (NVS) Switzerland $192.442B 16.51
AbbVie (ABBV) United States $149.625B 14.62
Novo Nordisk (NVO) Denmark $115.970B 18.54
Eli Lilly (LLY) United States $113.359B 20.98
Sanofi (SNY) France $105.440B 13.35
GlaxoSmithKline (GSK) United Kingdom $102.297B 13.66
Bristol-Myers Squibb (BMY) United States $99.527B 18.01
AstraZeneca (AZN) United Kingdom $96.554B 10.62